Wikipedia -WSS

Wikipedia

author：focus 2025-09-28 20:32:21 - browse：46

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： STAT Summit: Meghan O’Rourke on making chronic illness visible

entertainment

WSS

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Is there really a nursing shortage in the U.S.?

Elizabeth Holmes on track for early release from her 11

Beach reads and more: STAT's 2023 summer book list

HCA discloses massive data breach affecting 11 million patients

STAT Readout Newsletter: Biotech news today

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Moonlake's readout produced a cash windfall. Risks remain

Why 40% Americans with Parkinson’s don’t see a neurologist

Medical leaders decry Supreme Court decision on affirmative action

It's time to get medical device identifiers over the finish line

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

CZI to create biohub to build anti

Trump demands the U.S. pay no more for drugs than other countries … again

NIH fellows want a pay raise. Will that mean less money for grants?

Medical records are filled with copy

It's time to get medical device identifiers over the finish line

knowledge

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

CZI to create biohub to build anti

Leqembi, other new Alzheimer’s drugs require better biomarkers

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Why 40% Americans with Parkinson’s don’t see a neurologist

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

focus

entertainment

leisure time

leisure time